Use of AbobotulinumtoxinA for Cosmetic Treatments in the Neck, and Middle and Lower Areas of the Face: A Systematic Review.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
22 02 2021
Historique:
received: 18 01 2021
revised: 09 02 2021
accepted: 15 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 1 7 2021
Statut: epublish

Résumé

AbobotulinumtoxinA (aboBoNT-A) has been used for various cosmetic purposes, including minimization of moderate to severe lines, or other cosmetic indications, in the face and neck. We carried out a systematic review to identify all relevant evidence on the treatment approaches and outcomes of aboBoNT-A as a cosmetic treatment of the middle and lower areas of the face, and the neck. Embase, MEDLINE, Cochrane Library, congress proceedings and review bibliographies were searched for relevant studies. Identified articles were screened against pre-specified eligibility criteria. Of 560 unique articles identified, 10 were included for data extraction (three observational studies, 1 randomized controlled trial [with two articles] and five non-randomized trials). The articles provided data on gummy/asymmetric smile (2), marionette lines (5), masseter muscle volume (2), nasal wrinkles (2), perioral wrinkles (3) and the platysma muscle (4). All articles reporting on efficacy of aboBoNT-A demonstrated positive results, including reduction of wrinkles (5), reduction of masseter muscle (2) and degree of gummy smile (1) compared with before treatment. No serious adverse events were reported and patient satisfaction was high. In conclusion, positive findings support further research of aboBoNT-A for the middle and lower areas of the face, and in the neck, which are largely unapproved indications.

Identifiants

pubmed: 33671800
pii: toxins13020169
doi: 10.3390/toxins13020169
pmc: PMC7926328
pii:
doi:

Substances chimiques

Acetylcholine Release Inhibitors 0
Botulinum Toxins, Type A EC 3.4.24.69
abobotulinumtoxinA EC 3.4.24.69

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ipsen
ID : N/A

Références

Aesthet Surg J. 2016 Jul;36(7):810-20
pubmed: 26780945
Pharmacol Rev. 2017 Apr;69(2):200-235
pubmed: 28356439
J Cosmet Laser Ther. 2007 Dec;9(4):249-52
pubmed: 18236245
Aesthet Surg J. 2012 Sep;32(1 Suppl):8S-29S
pubmed: 22941910
Aesthet Surg J. 2015 Aug;35(6):NP141-6
pubmed: 26229133
Clin Cosmet Investig Dermatol. 2018 May 30;11:273-287
pubmed: 29910630
J Cosmet Dermatol. 2009 Dec;8(4):312-6
pubmed: 19958437
J Clin Aesthet Dermatol. 2020 Dec;13(12):E56-E83
pubmed: 33488922
JAMA. 2011 Jan 5;305(1):89-90
pubmed: 21205970
Toxins (Basel). 2018 Dec 13;10(12):
pubmed: 30551641
Plast Reconstr Surg. 2017 Jul;140(1):9e-17e
pubmed: 28654586
Aesthet Surg J. 2018 Oct 15;38(11):1225-1236
pubmed: 29506030
Syst Rev. 2013 Jun 13;2:40
pubmed: 23763852
Pharmacology. 2015;95(1-2):65-9
pubmed: 25613637
J Drugs Dermatol. 2013 Jan;12(1):80-4
pubmed: 23377332
J Drugs Dermatol. 2013 Dec;12(12):1356-62
pubmed: 24301236
Facial Plast Surg. 2010 Aug;26(4):303-9
pubmed: 20665408
Aesthetic Plast Surg. 2007 Sep-Oct;31(5):445-51; discussion 452-3
pubmed: 17674088
J Am Acad Dermatol. 2010 Dec;63(6):1042-51
pubmed: 21093661
J Drugs Dermatol. 2013 Dec;12(12):1363-7
pubmed: 24301237
J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1285-95
pubmed: 20569284
J Drugs Dermatol. 2010 Sep;9(9):1081-4
pubmed: 20865838
Dermatol Surg. 2013 Aug;39(8):1217-25
pubmed: 23650974
Clin Plast Surg. 2013 Apr;40(2):249-60
pubmed: 23506765
Plast Reconstr Surg. 2005 Mar;115(3):919-30
pubmed: 15731696
Aesthet Surg J. 2013 Mar;33(1 Suppl):13S-7S
pubmed: 23515194
Neurology. 1996 Apr;46(4):1158-60
pubmed: 8780112
J Clin Aesthet Dermatol. 2014 Feb;7(2):31-9
pubmed: 24587850
J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):249-59
pubmed: 10906647
Plast Reconstr Surg. 2016 Mar;137(3):518e-529e
pubmed: 26910696
Plast Reconstr Surg. 2018 Sep;142(3):640-649
pubmed: 29879010

Auteurs

Hassan Galadari (H)

College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, UAE.

Ibrahim Galadari (I)

College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, UAE.

Riekie Smit (R)

Riekie Smit Practice, Pretoria 0182, South Africa.

Inna Prygova (I)

Ipsen Pharmaceutical, 92100 Boulogne-Billancourt, France.

Alessio Redaelli (A)

Visconti di Modrone Medical Center, 20122 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH